China SXT Pharmaceuticals (FRA:2RY2) Insider Ownership: 0.00 % (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2RY2 China SXT Pharmaceuticals Inc FRA:2RY2
19 GF Score
Price €3.04
GF Value €5.74
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Insider Ownership?

China SXT Pharmaceuticals FRA:2RY2 -2.38% 19 Insider Ownership is 0.00 % as of Aug. 13, 2026. GuruFocus rates FRA:2RY2 with a GF Score™ of 19/100 and a GF Value™ of €5.74 (Possible Value Trap). The stock has 8 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, China SXT Pharmaceuticals's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, China SXT Pharmaceuticals's Institutional Ownership is 0.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, China SXT Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 161.04%.

China SXT Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals Insider Ownership Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2RY2
19GF Score
China SXT Pharmaceuticals Inc FRA:2RY2
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
China SXT Pharmaceuticals (FRA:2RY2) has a Insider Ownership of 0.00 % as of Aug. 13, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on China SXT Pharmaceuticals and its competitors.
Is China SXT Pharmaceuticals' Insider Ownership too high?
China SXT Pharmaceuticals' current Insider Ownership is 0.00 %. Overall, China SXT Pharmaceuticals has a GF Score™ of 19/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Insider Ownership compare to CBIH and UPC?
China SXT Pharmaceuticals' Insider Ownership of 0.00 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on China SXT Pharmaceuticals and its competitors. China SXT Pharmaceuticals's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (FRA:2RY2) is currently considered Possible Value Trap. The stock's GF Value™ is €5.74, compared to a current price of €3.04 — trading 47.1% below its estimated fair value. The current Insider Ownership is 0.00 %. China SXT Pharmaceuticals' overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY2), the current Insider Ownership is 0.00 % as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (FRA:2RY2) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued. The current stock price of €3.04 is trading 47.1% below its estimated GF Value™ of €5.74. GuruFocus considers China SXT Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:2RY2:

  • Insider Ownership: 0.00 %
  • GF Value™: €5.74 vs. price of €3.04 (47.1% below fair value)
  • GF Score™: 19/100 with 8 warning signs

No single metric tells the full story. See the FRA:2RY2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score

Get the complete analysis for FRA:2RY2

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€5.74
GF Value